Curated News
By: NewsRamp Editorial Staff
August 06, 2026

VERAXA Advances VXA-222 Cancer Program and Expands Patent Portfolio

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • VERAXA's VXA-222 advances, strengthening its position in oncology with a robust patent portfolio to outpace rivals.
  • Following OmniAb discovery, VERAXA engineers the bsADC candidate, leveraging proprietary linker and conjugation tech for preclinical validation.
  • This milestone brings VERAXA closer to novel cancer therapies, offering hope for patients with difficult-to-treat cancers.
  • VERAXA holds over 50 patents across 26 families, extending protection to 2047, a rare feat for an emerging biotech.

Impact - Why it Matters

This news matters because VERAXA's progress in advancing VXA-222 and expanding its intellectual property signals growing momentum in the development of next-generation cancer therapies. For investors, the strengthened patent portfolio could provide long-term competitive advantages and revenue streams. For patients, this could eventually lead to more effective treatments for difficult-to-treat cancers. The company's diversified pipeline and strategic collaborations also highlight its potential to become a key player in the biotech industry.

Summary

VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced a significant milestone in its oncology pipeline: its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase into the next stage of development. This progress follows the successful completion of the discovery phase of a collaboration with OmniAb Inc., which began in May 2025. Under the collaboration, OmniAb delivered a portfolio of therapeutic antibody binders, and VERAXA will now engineer the final bispecific ADC candidate, leveraging its proprietary antibody engineering, linker, and conjugation technologies to advance preclinical validation.

VXA-222 is not based on VERAXA's BiTAC platform, but it represents one of the company's more advanced programs, underscoring the breadth of its R&D efforts. In tandem with this pipeline advancement, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, as well as additional patents covering conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with new filings expected to extend protection into at least 2047.

This dual progress—pipeline advancement and IP expansion—positions VERAXA to strengthen its diversified oncology portfolio, which includes bispecific ADCs, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers. For more details, read the full release on Read More. The latest updates are available at https://ibn.fm/VRXA.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, VERAXA Advances VXA-222 Cancer Program and Expands Patent Portfolio

blockchain registration record for this content.